Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
35 Pages - GMD12095
$1,500.00

Summary

Global Markets Direct’s, ‘Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2014’, provides an overview of the Neurim Pharmaceuticals Ltd’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Neurim Pharmaceuticals Ltd’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Neurim Pharmaceuticals Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Neurim Pharmaceuticals Ltd’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Neurim Pharmaceuticals Ltd’s pipeline products

Reasons to buy

- Evaluate Neurim Pharmaceuticals Ltd’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Neurim Pharmaceuticals Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Neurim Pharmaceuticals Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Neurim Pharmaceuticals Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neurim Pharmaceuticals Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Neurim Pharmaceuticals Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Neurim Pharmaceuticals Ltd Snapshot 5
Neurim Pharmaceuticals Ltd Overview 5
Key Information 5
Key Facts 5
Neurim Pharmaceuticals Ltd - Research and Development Overview 6
Key Therapeutic Areas 6
Neurim Pharmaceuticals Ltd - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Neurim Pharmaceuticals Ltd - Pipeline Products Glance 11
Neurim Pharmaceuticals Ltd - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Neurim Pharmaceuticals Ltd - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Neurim Pharmaceuticals Ltd - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Neurim Pharmaceuticals Ltd - Drug Profiles 16
melatonin ER 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
piromelatine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Neu-120 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Neu-105 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Neu-164 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Neu-240 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Neu-AZ1 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Neu-P12 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Neurim Pharmaceuticals Ltd - Pipeline Analysis 25
Neurim Pharmaceuticals Ltd - Pipeline Products by Target 25
Neurim Pharmaceuticals Ltd - Pipeline Products by Route of Administration 27
Neurim Pharmaceuticals Ltd - Pipeline Products by Molecule Type 28
Neurim Pharmaceuticals Ltd - Pipeline Products by Mechanism of Action 29
Neurim Pharmaceuticals Ltd - Recent Pipeline Updates 32
Neurim Pharmaceuticals Ltd - Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables
Neurim Pharmaceuticals Ltd, Key Information 5
Neurim Pharmaceuticals Ltd, Key Facts 5
Neurim Pharmaceuticals Ltd - Pipeline by Indication, 2014 8
Neurim Pharmaceuticals Ltd - Pipeline by Stage of Development, 2014 9
Neurim Pharmaceuticals Ltd - Monotherapy Products in Pipeline, 2014 10
Neurim Pharmaceuticals Ltd - Phase III, 2014 11
Neurim Pharmaceuticals Ltd - Phase II, 2014 12
Neurim Pharmaceuticals Ltd - Phase I, 2014 13
Neurim Pharmaceuticals Ltd - Preclinical, 2014 14
Neurim Pharmaceuticals Ltd - Discovery, 2014 15
Neurim Pharmaceuticals Ltd - Pipeline by Target, 2014 25
Neurim Pharmaceuticals Ltd - Pipeline by Route of Administration, 2014 27
Neurim Pharmaceuticals Ltd - Pipeline by Molecule Type, 2014 28
Neurim Pharmaceuticals Ltd - Pipeline Products by Mechanism of Action, 2014 30
Neurim Pharmaceuticals Ltd - Recent Pipeline Updates, 2014 32
Neurim Pharmaceuticals Ltd, Other Locations 33

List of Figures
Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Indication, 2014 7
Neurim Pharmaceuticals Ltd - Pipeline by Stage of Development, 2014 9
Neurim Pharmaceuticals Ltd - Monotherapy Products in Pipeline, 2014 10
Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Target, 2014 25
Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Route of Administration, 2014 27
Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Molecule Type, 2014 28
Neurim Pharmaceuticals Ltd - Pipeline Products by Top 10 Mechanism of Action, 2014 29

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax